FMP
NuGenerex Immuno-Oncology, Inc.
NUGX
OTC
Inactive Equity
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
0.0001 USD
0 (0%)
About
ceo
Mr. Joseph Moscato
sector
Healthcare
industry
Biotechnology
exchange
OTC
Description
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer. The company was formerly known as Antigen Express, Inc. The company was founded in 1993 and is based in Miramar, Florida. NuGenerex Immuno-Oncology, Inc.is a subsidiary of Generex Biotechnology Corporation.
CIK
0001804585
ISIN
US67053X1028
CUSIP
67053X102
Address
10102 USA Today Way
Phone
416 364 2551
Country
US
Employee
6
IPO Date
Mar 15, 2021
Key Executives
Name
Title
Pay
Year Born
Dr. Jason B. Terrell M.D.
Chief Medical Officer
0
1973
Mr. Richard D. Purcell
Executive Vice President of R&D and Dire...
0
1961
Mr. Anthony S. Crisci CPA, Esq.
Corporation Counsel, Chief Legal Officer...
0
1971
Mr. Mark Corrao
Chief Financial Officer
0
1958
Mr. Joseph Moscato
Chief Executive Officer, Pres & Chairman
0
1964
Dr. Eric von Hofe Ph.D.
Chief Scientific Officer
0
1955
As of December 31, 2024, the total employee count stands at 6, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
